home / stock / tpst / tpst quote
Last: | $3.38 |
---|---|
Change Percent: | -0.29% |
Open: | $3.41 |
Close: | $3.38 |
High: | $3.5839 |
Low: | $3.35 |
Volume: | 329,490 |
Last Trade Date Time: | 05/15/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.38 | $3.41 | $3.38 | $3.5839 | $3.35 | 329,490 | 05-15-2024 |
$3.4 | $3.25 | $3.4 | $3.45 | $3.245 | 435,422 | 05-14-2024 |
$3.28 | $3.25 | $3.28 | $3.43 | $3.22 | 345,717 | 05-13-2024 |
$3.25 | $3.54 | $3.25 | $3.5599 | $3.17 | 490,889 | 05-10-2024 |
$3.47 | $3.45 | $3.47 | $3.57 | $3.44 | 202,084 | 05-09-2024 |
$3.47 | $3.52 | $3.47 | $3.55 | $3.44 | 297,641 | 05-08-2024 |
$3.62 | $3.71 | $3.62 | $3.7636 | $3.595 | 234,117 | 05-07-2024 |
$3.73 | $3.75 | $3.73 | $3.79 | $3.6 | 206,922 | 05-06-2024 |
$3.69 | $3.6 | $3.69 | $3.77 | $3.5568 | 421,053 | 05-03-2024 |
$3.54 | $3.67 | $3.54 | $3.74 | $3.48 | 482,694 | 05-02-2024 |
$3.62 | $3.47 | $3.62 | $3.67 | $3.4201 | 257,746 | 05-01-2024 |
$3.47 | $3.44 | $3.47 | $3.54 | $3.39 | 246,483 | 04-30-2024 |
$3.44 | $3.51 | $3.44 | $3.7164 | $3.44 | 306,788 | 04-29-2024 |
$3.54 | $3.51 | $3.54 | $3.63 | $3.38 | 402,988 | 04-26-2024 |
$3.48 | $3.37 | $3.48 | $3.49 | $3.31 | 289,664 | 04-25-2024 |
$3.44 | $3.45 | $3.44 | $3.57 | $3.36 | 652,486 | 04-24-2024 |
$3.42 | $3.28 | $3.42 | $3.47 | $3.2441 | 396,931 | 04-23-2024 |
$3.24 | $3.1 | $3.24 | $3.28 | $3.08 | 391,140 | 04-22-2024 |
$3.1 | $3.16 | $3.1 | $3.26 | $3.0611 | 386,258 | 04-19-2024 |
$3.17 | $3.3 | $3.17 | $3.34 | $3.17 | 316,619 | 04-18-2024 |
News, Short Squeeze, Breakout and More Instantly...
Tempest Therapeutics Inc. Company Name:
TPST Stock Symbol:
NASDAQ Market:
Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAP Reported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual Meeting Published positive data from the Phase 1 Trial of TPST-1120 in patients with advanced soli...
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical...
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-q...